Susceptibility to inflammatory bowel diseases depends upon interactions between the genetics of the individual and induction of chronic mucosal inflammation. We hypothesized that administration of dietary phenolics, caffeic acid and rutin, would suppress upregulation of inflammatory markers and intestinal damage in a mouse model of colitis. Colitis was induced in C3H/ HeOuJ mice (8 weeks old, 6 male/6 female per treatment) with 1.25% dextran sulfate sodium (DSS) for 6 d in their drinking water. Rutin (1.0 mmol (524 mg)/kg in diet), caffeic acid (1.0 mmol (179 mg)/kg in diet), and hypoxoside extract (15 mg/d, an anticolitic phenolic control) were fed to the mice for 7 d before and during DSS treatment, as well as without DSS treatment. Body weight loss was prevented by rutin and caffeic acid during DSS treatment. Colon lengths in mice fed caffeic acid and hypoxoside during DSS treatment were similar to DSS-negative control. Food intake was improved and myeloperoxidase (MPO) was decreased with each phenolic treatment in DSS-treated mice compared with DSS treatment alone. Colonic mRNA expression of IL-17 and iNOS were inhibited when IL-4 was increased by each phenolic treatment combined with DSS, whereas CYP4B1 mRNA was increased only by caffeic acid in DSS-treated mice, compared with DSS treatment alone. Colonic and cecal histopathology scores of DSS-treated mice were significantly more severe (P < 0.01) than in mice fed caffeic acid before and during DSS treatment, based on mucosal height, necrosis, edema, erosion, and inflammatory cell infiltration. Although both rutin and caffeic acid suppressed the expression of selected inflammatory markers, only caffeic acid protected against DSS-induced colitis, in association with normalization of CYP4B1 expression. The inhibition of DSS-induced colitic pathology by caffeic acid was mediated by mechanisms in addition to anti-inflammatory effects that deserve further study.
Get full access to this article
View all access options for this article.
References
1.
Podolsky DK. Inflammatory bowel disease. N Engl J Med47:417–429, 2002.
2.
Shah S. Dietary factors in the modulation of inflammatory bowel disease activity. MedGenMed9:60, 2007.
3.
Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int J Cancer60:330–333, 1995.
4.
Hutto DL, Galvin JE, Wannemuehler MJ. Morphological and temporal characterisation of lesions in an enhanced model of Serpulina hyodysenteriae infection. J Med Microbiol47:275–280, 1998.
5.
Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, Hostetter J, Wannemuehler MJ. Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut56:934–940, 2007.
6.
Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol114:385–391, 1998.
7.
Stevceva L, Pavli P, Buffinton G, Wozniak A, Doe WF. Dextran sodium sulphate–induced colitis activity varies with mouse strain but develops in lipopolysaccharide-unresponsive mice. J Gastroenterol Hepatol14:54–60, 1999.
Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology120:622–635, 2001.
12.
Fitzpatrick LR, Wang J, Le T. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial peptidoglycan polysaccharide–induced colitis in rats. J Pharmacol Exp Ther299:915–920, 2001.
13.
Kwon KH, Murakami A, Tanaka T. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium–induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol69:395–406, 2005.
14.
Bereta J, Bereta M, Allison AC, Kruger PB, Koj A. Inhibitory effect of dicatechol rooperol on VCAM-1 and iNOS expression in cytokine-stimulated endothelium. Life Sci60:325–334, 1997.
15.
Dietzsch E, Albrecht CF, Parker MI. Effect of rooperol on collagen synthesis and cell growth. IUBMB Life48:321–325, 1999.
16.
Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim48:137–143, 1999.
17.
Murakami A, Hayashi R, Tanaka T, Kwon KH, Ohigashi H, Safitri R. Suppression of dextran sodium sulfate–induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem Pharmacol66:1253–1261, 2003.
18.
Nibbelink SK, Wannemuehler MJ. An enhanced murine model for studies of Serpulina (Treponema) hyodysenteriae pathogenesis. Infect Immun60:3433–3436, 1992.
19.
Jergens AE, Dorn A, Wilson J, Dingbaum K, Henderson A, Liu Z, Hostetter J, Evans RB, Wannemuehler MJ. Induction of differential immune reactivity to members of the flora of gnotobiotic mice following colonization with Helicobacter bilis or Brachyspira hyodysenteriae. Microbes Infect8:1602–1610, 2006.
20.
Overbergh L, Giulietti A, Valckx D, Decallonne R, Bouillon R, Mathieu C. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech14:33–43, 2003.
21.
Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine11:305–312, 1999.
22.
Xia Y, Zweier JL. Measurement of myeloperoxidase in leukocyte-containing tissues. Anal Biochem245:93–96, 1997.
23.
Palic D, Andreasen CB, Menzel BW, Roth JA. A rapid, direct assay to measure degranulation of primary granules in neutrophils from kidney of fathead minnow (Pimephales promelas Rafinesque, 1820) Fish and Shellfish. Immunology19:217–227, 2005.
24.
Clifford MN. Chlorogenic acids and other cinnamates—nature, occurrence and dietary burden. J Sci Food Agric79:362–372, 1999
25.
Radtke J, Linseisen J, Wolfram G. Phenolic acid intake of adults in a Bavarian subgroup of the national food composition survey. Z Ernahrungswiss37:190–197, 1998.
26.
Bobe G, Weinstein SJ, Albanes D, Hirvonen T, Ashby J, Taylor PR, Virtamo J, Stolzenberg-Solomon RZ. Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). Cancer Epidemiol Biomarkers Prev17:553–562, 2008.
27.
Mayer L. IBD: immunological research at the Mount Sinai hospital. Mt Sinai J Med67:208–213, 2000.
28.
Shanahan F. Crohn’s disease. Lancet359:62–69, 2002.
29.
Ciancio MJ, Chang EB. Epithelial secretory response to inflammation. Ann N Y Acad Sci664:210–221, 1992.
30.
Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest69:238–249, 1993.
31.
Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol10:1379–1383, 2002.
32.
Ek RO, Serter M, Ergin K, Yildiz Y, Cecen S, Kavak T, Yenisey C. The effects of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis in ovariectomized rats. Dig Dis Sci53:1609–1617, 2008.
33.
Celik S, Gorur S, Aslantas O, Erdogan S, Ocak S, Hakverdi S. Caffeic acid phenethyl ester suppresses oxidative stress in Escherichia coli–induced pyelonephritis in rats. Mol Cell Biochem297:131–138, 2007.
34.
La Casa C, Villegas I, Alarcon de la Lastra C, Motilva V, Martin Calero MJ. Evidence for protective and antioxidant properties of rutin, a natural flavone, against ethanol induced gastric lesions. J Ethnopharmacol71:45–53, 2000.
35.
Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut52:65–70, 2003.
36.
Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity21:467–476, 2004.
37.
Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol288:G1328–G1338, 2005.
38.
Park JH, Lee JK, Kim HS, Chung ST, Eom JH, Kim KA, Chung SJ, Paik SY, Oh HY. Immunomodulatory effect of caffeic acid phenethyl ester in BALB/c mice. Int Immunopharmacol4:429–436, 2004.
39.
Ansorge S, Reinhold D, Lendeckel U. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch [C]58:580–589, 2003.
40.
Baer BR, Rettie AE. CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab Rev38: 451–476, 2006.
41.
Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol43:149–173, 2003.
42.
Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab5:235–243, 2004.
43.
Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Expression patterns of mouse and human CYP orthologs (families 1–4) during development and in different adult tissues. Arch Biochem Biophys436:50–61, 2005.
44.
McKinnon RA, Burgess WM, Gonzalez FJ, Gasser R, McManus ME. Species-specific expression of CYP4B1 in rabbit and human gastrointestinal tissues. Pharmacogenetics4:260–270, 1994.
45.
Stoilov I, Krueger W, Mankowski D, Guernsey L, Kaur A, Glynn J, Thrall RS. The cytochromes P450 (CYP) response to allergic inflammation of the lung. Arch Biochem Biophys456:30–38, 2006.
46.
Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther9:1261–1273, 1998.
47.
Frank S, Steffens S, Fischer U, Tlolko A, Rainov NG, Kramm CM. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther9:178–188, 2002.
48.
Mohr L, Rainov NG, Mohr UG, Wands JR. Rabbit cytochrome P450 4B1: a novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther7:1008–1014, 2000.
49.
Iber H, Chen Q, Morgan ET. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NFκB binding at the transcription start site. Arch Biochem Biophys377:187–194, 2000.
50.
Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A, Pessayre D. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther289:649–655, 1999.
51.
Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem281:17882–17889, 2006.
52.
Khatsenko OG, Boobis AR, Gross SS. Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. Toxicol Lett90:207–216, 1997.
53.
Takemura S, Minamiyama Y, Imaoka S, Funae Y, Hirohashi K, Inoue M, Kinoshita H. Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol30:1035–1044, 1999.
54.
Atik E, Gorur S, Kiper AN. The effect of caffeic acid phenethyl ester (CAPE) on histopathological changes in testicular ischemia-reperfusion injury. Pharmacol Res54:293–297, 2006.
55.
Song YS, Park EH, Hur GM, Ryu YS, Lee YS, Lee JY, Kim YM, Jin C. Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity. Cancer Lett175:53–61, 2002.
